Patients in the response-guided therapy arm ( D ) with an extended rapid virological response ( eRVR2 : HCV RNA < 15 IU/ml during Weeks 2-10 ) stopped all therapy at Week 12 ; non-eRVR2 patients continued all treatment to Week 24 .